BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.

中文翻译：

---

BCMA 定向治疗早期复发和/或难治性多发性骨髓瘤


BCMA 导向的嵌合抗原受体 T 细胞疗法和双特异性 T 细胞接合剂正在转向多发性骨髓瘤的早期治疗。此外，在首次或随后复发时使用 BCMA 靶向抗体-药物偶联物 belantamab mafodotin 进行联合治疗有可能提高该疾病患者的生存率。治疗选择数量的增加使得治疗选择和排序变得越来越复杂。